Background: Ivabradine is an inhibitor of mixed Na+-K+ current that could combine with HCN channels to reduce the trans-membrane velocity of funny current (If), heart rate, and cardiac efficiency, and thus be used for the treatment of cardiovascular diseases such as chronic heart failure. As an ion channel blocker, Ivabradine is also a poten-tial antiarrhythmic agent. Material/Methods: Twelve aging dogs (8–10 years old) underwent rapid atrial pacing for 2 months to induce age-related AF in this study. The dogs were randomly divided into the Ivabradine group and aging-AF group. The effects of Ivabradine on the electrophysiological parameters, including the effective refractory period (ERP) of the pulmonary veins and atrium, duration of AF, a...
Increased heart rate (HR) is associated with deleterious effects on several disease conditions. Chro...
AZD1305 is an investigational antiarrhythmic agent for management of atrial fibrillation. It blocks ...
Background: The electrophysiologic and antiarrhythmic effects of a new class III antiar-rhythmic dru...
A large number of studies in healthy and asymptomatic subjects, as well as patients with already est...
Background: Ivabradine (IVA), a heart rate (HR) lowering drug, acts by selective inhibition of the c...
Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillati...
Ivabradine (IVB) is a heart rate lowering agent that acts via selective inhibition of the pacemaker ...
Cardiac remodeling can cause ventricular dysfunction and progress to heart failure, a cardiovascular...
AimA major risk of myocardial ischemia (MI) is the onset of ventricular fibrillation (VF). Our study...
By selectively and specifically inhibiting the cardiac pacemaker If current, the If inhibitors lower...
Background-AZD1305 is an investigational antiarrhythmic agent for management of atrial fibrillation....
Background: We compared cardiac electrophysiological indicators and regional expression levels of ca...
Introduction: Patients with heart failure and left bundle branch block (LBBB) are frequently treated...
International audienceAIMS: To investigate the adaptations of left ventricular function and calcium ...
Ibutilide is a newer class-III antiarrhythmic agent approved for clinical use. We sought to investig...
Increased heart rate (HR) is associated with deleterious effects on several disease conditions. Chro...
AZD1305 is an investigational antiarrhythmic agent for management of atrial fibrillation. It blocks ...
Background: The electrophysiologic and antiarrhythmic effects of a new class III antiar-rhythmic dru...
A large number of studies in healthy and asymptomatic subjects, as well as patients with already est...
Background: Ivabradine (IVA), a heart rate (HR) lowering drug, acts by selective inhibition of the c...
Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular fibrillati...
Ivabradine (IVB) is a heart rate lowering agent that acts via selective inhibition of the pacemaker ...
Cardiac remodeling can cause ventricular dysfunction and progress to heart failure, a cardiovascular...
AimA major risk of myocardial ischemia (MI) is the onset of ventricular fibrillation (VF). Our study...
By selectively and specifically inhibiting the cardiac pacemaker If current, the If inhibitors lower...
Background-AZD1305 is an investigational antiarrhythmic agent for management of atrial fibrillation....
Background: We compared cardiac electrophysiological indicators and regional expression levels of ca...
Introduction: Patients with heart failure and left bundle branch block (LBBB) are frequently treated...
International audienceAIMS: To investigate the adaptations of left ventricular function and calcium ...
Ibutilide is a newer class-III antiarrhythmic agent approved for clinical use. We sought to investig...
Increased heart rate (HR) is associated with deleterious effects on several disease conditions. Chro...
AZD1305 is an investigational antiarrhythmic agent for management of atrial fibrillation. It blocks ...
Background: The electrophysiologic and antiarrhythmic effects of a new class III antiar-rhythmic dru...